Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-01-06 @ 9:26 PM
Study NCT ID:
NCT02156804
Status:
COMPLETED
Last Update Posted:
2020-09-11
First Post:
2014-05-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-07
Start Date Type:
ACTUAL
Primary Completion Date:
2019-01-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-01-18
Completion Date Type:
ACTUAL
First Submit Date:
2014-05-29
First Submit QC Date:
None
Study First Post Date:
2014-06-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-01-10
Results First Submit QC Date:
None
Results First Post Date:
2020-02-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-09
Last Update Post Date:
2020-09-11
Last Update Post Date Type:
ACTUAL